Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $123.00 at Oppenheimer

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target decreased by equities research analysts at Oppenheimer from $184.00 to $123.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the biotechnology company's stock. Oppenheimer's price target indicates a potential upside of 229.69% from the stock's previous close.

A number of other analysts have also recently issued reports on SRPT. Cantor Fitzgerald reiterated an "overweight" rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Needham & Company LLC dropped their price target on shares of Sarepta Therapeutics from $183.00 to $125.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley dropped their price target on shares of Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price target for the company from $161.00 to $87.00 in a research report on Monday, March 31st. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $131.22.

Sarepta Therapeutics Stock Up 2.9%

NASDAQ SRPT traded up $1.04 during trading on Wednesday, reaching $37.31. The company's stock had a trading volume of 3,394,676 shares, compared to its average volume of 1,628,659. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $3.67 billion, a PE ratio of 29.84 and a beta of 0.85. The business has a 50-day moving average price of $66.84 and a 200-day moving average price of $100.44. Sarepta Therapeutics has a 1-year low of $35.46 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. Sarepta Therapeutics's revenue was up 80.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 earnings per share. On average, research analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. The trade was a 8.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.70% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Manchester Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $30,000. Center for Financial Planning Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $31,000. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $36,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.